Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC
WEDNESDAY, Sept. 14, 2022 (HealthDay News) — Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy r…
Learn More